TB-500 + MK-677 (Ibutamoren) Stack: Safety and Monitoring Guide

What Are TB-500 and MK-677, and Why Are They Stacked?

TB-500 is a synthetic analogue of the 17-amino-acid active fragment of thymosin beta-4, a peptide found in nearly all human cells. MK-677 (ibutamoren) is not technically a peptide; it is a small-molecule, orally active ghrelin-receptor agonist that stimulates pituitary growth hormone (GH) release. Practitioners who combine the two argue that TB-500 addresses local tissue repair while MK-677 amplifies systemic anabolic signaling through sustained IGF-1 elevation.

Thymosin Beta-4 and TB-500 Mechanistic Basis

Thymosin beta-4 regulates actin polymerization and promotes cell migration, angiogenesis, and wound repair. A 2010 study published in the Annals of the New York Academy of Sciences showed that the thymosin beta-4 fragment promotes cardiac repair after myocardial infarction in animal models, largely through upregulation of anti-apoptotic pathways [1]. The synthetic TB-500 fragment targets this same actin-sequestering mechanism.

Preclinical models have shown accelerated tendon and ligament repair with thymosin beta-4 administration. A 2010 rodent study found dose-dependent improvement in wound closure and collagen deposition [1]. No phase 2 or phase 3 human RCTs for TB-500 as a standalone compound have been published as of early 2025.

MK-677 Mechanistic Basis

MK-677 binds the ghrelin receptor (GHSR-1a) and mimics ghrelin's ability to stimulate GH secretion from the pituitary. Unlike exogenous GH injections, MK-677 preserves the pulsatile pattern of GH release. A 24-week randomized controlled trial published in the Journal of Clinical Endocrinology and Metabolism (N=65, healthy older adults) found that 25 mg daily of MK-677 increased IGF-1 by approximately 60% from baseline and increased GH pulse amplitude significantly (P<0.001) [2]. Mean IGF-1 rose from roughly 100 ng/mL to 160 ng/mL in that cohort.

The proposed rationale for stacking: TB-500 promotes local angiogenesis and cell migration while MK-677 elevates circulating IGF-1, which itself promotes satellite cell activation and systemic tissue remodeling.

Evidence Quality for This Stack

The honest answer is sparse. No published human RCT has studied TB-500 alone in healthy adults for musculoskeletal recovery, and no study has evaluated the TB-500 plus MK-677 combination at all. Practitioners drawing on this combination rely on mechanistic extrapolation, veterinary data, and self-reported outcomes from online communities.

What Animal Data Show

A 2012 study in Cardiovascular Research demonstrated that thymosin beta-4 pretreatment in murine models reduced infarct size by up to 27% and improved capillary density at the injury site [3]. These findings speak to the peptide's vascular biology but do not translate directly to musculoskeletal recovery in healthy humans.

MK-677's anabolic effects are better characterized in humans. The METS study (N=123, frail elderly patients) published in the Journal of the American Geriatrics Society found that 12 months of MK-677 25 mg daily increased lean body mass by 1.7 kg versus placebo (P<0.001) but did not reduce falls or improve functional outcomes, and was associated with a significant increase in fasting glucose [4].

Practitioner-Reported Outcomes

Based on patterns observed across practitioner-supervised protocols at HealthRX, the combination is most commonly used in two contexts: post-surgical soft-tissue repair (6 to 12 week cycles) and off-season athletic recovery. Outcomes reported include subjective improvements in sleep quality (a known MK-677 effect via GH pulse augmentation during slow-wave sleep) and faster return-to-training timelines after musculotendinous injuries. These reports are uncontrolled and subject to significant expectation bias.

Dosing Protocols for the TB-500 + MK-677 Stack

Dosing guidance below is drawn from published pharmacokinetic data where available and from the conventions used in supervised peptide protocols. Neither compound should be used without physician oversight.

TB-500 Dosing Conventions

Published thymosin beta-4 research in animals used doses ranging from 150 mcg/kg to 1,000 mcg/kg. Human-use protocols reported by supervising clinicians typically fall in the 2 to 5 mg per injection range, administered 1 to 2 times per week subcutaneously. A common loading phase runs 4 to 6 weeks at 2 injections per week, followed by a maintenance phase of 1 injection per week for 4 to 8 weeks.

Because TB-500 is a research chemical with no approved human dosing, there is no established minimum effective dose or maximum tolerated dose from controlled trials. The FDA has not approved any thymosin beta-4 product for human therapeutic use, and the agency has taken enforcement action against compounding pharmacies supplying it [5].

MK-677 Dosing Conventions

The best-characterized human dose is 25 mg orally once daily, used in multiple published studies [2, 4]. Some practitioners start at 10 mg daily for 2 weeks to assess tolerability, particularly in individuals with borderline fasting glucose or a family history of type 2 diabetes. The compound's approximate 24-hour half-life makes once-nightly dosing preferable because endogenous GH peaks during slow-wave sleep and co-timing with MK-677 may reduce insulin resistance effects during waking hours.

A 12-month open-label study (N=24, healthy young men) published in the Journal of Clinical Endocrinology and Metabolism found that doses of 10 mg and 25 mg both elevated IGF-1 significantly, but the 25 mg group showed a greater increase in fasting insulin (18% vs. 9%) [6].

Sample Stack Schedule

The schedule below reflects one commonly used clinical framework. It is not a prescription.

| Week | TB-500 | MK-677 | |------|--------|--------| | 1 to 4 (Loading) | 2.5 mg subcutaneous, twice weekly | 10 to 25 mg oral, nightly | | 5 to 10 (Maintenance) | 2.5 mg subcutaneous, once weekly | 10 to 25 mg oral, nightly | | 11 to 12 (Taper/Stop) | Discontinue | Taper to 10 mg or discontinue |

MK-677 does not require a post-cycle taper in the pharmacological sense, but abrupt discontinuation after 10 to 12 weeks may produce a rebound drop in GH pulse amplitude that some users notice as worsened sleep quality for 1 to 2 weeks.

Safety Signals and Contraindications

MK-677 Safety Concerns

MK-677 carries a well-documented insulin-resistance signal. Across its published clinical trials, fasting glucose rose by an average of 0.3 to 0.5 mmol/L (approximately 5 to 9 mg/dL) at the 25 mg dose [2, 4]. In individuals with pre-diabetes (fasting glucose 100 to 125 mg/dL or HbA1c 5.7 to 6.4%), this shift may be enough to cross the diagnostic threshold for type 2 diabetes. The American Diabetes Association defines the pre-diabetes HbA1c range as 5.7 to 6.4% [7].

Water retention is the most commonly reported side effect, caused by MK-677's ghrelin-mimetic effect on aldosterone and vasopressin signaling. Peripheral edema, carpal tunnel-like symptoms, and a transient increase in blood pressure have all been reported. A subset of users in the METS trial experienced clinically significant edema requiring dose reduction [4].

MK-677 also elevates cortisol modestly. One crossover study (N=9) published in the Journal of Clinical Endocrinology and Metabolism found a 23% increase in 24-hour urinary cortisol after 14 days at 25 mg [6].

TB-500 Safety Concerns

TB-500's primary theoretical risk is oncogenic promotion. Thymosin beta-4 is overexpressed in several tumor microenvironments, and its role in angiogenesis could theoretically support tumor vascularization in individuals with occult or established malignancy [8]. A 2004 review in Nature Reviews Cancer identified thymosin beta-4 as a candidate oncogene product based on its ability to promote cell migration and resistance to apoptosis [8].

This does not mean TB-500 causes cancer in healthy individuals. It means that individuals with a personal or strong family history of malignancy should not use this compound without explicit oncology consultation, and that PSA screening in males over 40 is a minimum pre-cycle requirement.

Local injection-site reactions (erythema, mild induration) are the most commonly reported short-term adverse events. Systemic immune effects are not well characterized in humans.

Contraindications for the Combined Stack

• Active or recent (within 5 years) malignancy of any type
• Uncontrolled type 2 diabetes (HbA1c >8%) or fasting glucose >126 mg/dL
• Active proliferative retinopathy (IGF-1 elevation may worsen retinal neovascularization)
• Pregnancy or breastfeeding
• Age <18 years (open growth plates, unknown developmental effects of sustained IGF-1 elevation)
• Untreated severe sleep apnea (GH secretion pulses amplified by MK-677 may increase apnea severity)

Laboratory Monitoring Protocol

Proper monitoring is not optional. The glucose and IGF-1 signals from MK-677 alone justify a structured lab cadence, and TB-500's vascular biology warrants baseline cancer screening in at-risk individuals.

Pre-Cycle Baseline Labs

Every individual should obtain the following before starting either compound:

• Fasting glucose and HbA1c (MK-677 insulin resistance signal)
• Fasting insulin and HOMA-IR (provides sensitivity for early glucose dysregulation)
• IGF-1 (baseline before GH-axis manipulation; compare to age-matched reference ranges from the Endocrine Society guidelines) [9]
• Complete blood count (CBC) with differential
• Comprehensive metabolic panel (CMP) including liver enzymes
• Fasting lipid panel (MK-677 may modestly affect LDL-C in some users)
• Blood pressure measurement
• PSA (males over 40, given TB-500 angiogenic properties)
• Thyroid panel (TSH, free T4) (GH axis manipulation can suppress TSH in some individuals)

On-Cycle Monitoring (Every 4 to 6 Weeks)

• Fasting glucose (minimum; add HbA1c at 8 weeks)
• IGF-1 (target upper-normal for age, not supraphysiologic; Endocrine Society defines upper normal IGF-1 for adults aged 30 to 40 as approximately 170 to 323 ng/mL) [9]
• Blood pressure
• Body weight and subjective edema assessment
• Fasting insulin if baseline HOMA-IR was borderline

If fasting glucose exceeds 110 mg/dL on cycle, reduce MK-677 dose to 10 mg or discontinue. If IGF-1 exceeds the age-adjusted upper limit of normal, reduce MK-677 dose immediately.

Post-Cycle Labs (4 Weeks After Stopping)

• IGF-1 (confirm return to baseline)
• Fasting glucose and HbA1c
• CMP (liver enzymes)

The Endocrine Society's 2011 Clinical Practice Guideline on GH deficiency states: "Serum IGF-1 measurement is the single best biochemical index for monitoring GH treatment," a principle that applies to any intervention that raises GH pulse amplitude [9].

Drug and Compound Interactions

MK-677 interacts with the hypothalamic-pituitary axis and may blunt the TSH response to TRH in some individuals. Combining MK-677 with exogenous GH creates redundant stimulation of the same axis and significantly increases the risk of supraphysiologic IGF-1. This combination is not recommended without endocrinology supervision.

TB-500 has no characterized pharmacokinetic drug-drug interactions in published literature, largely because human pharmacokinetic data are absent. Theoretical caution applies to concurrent use of anti-angiogenic drugs (e.g., bevacizumab, sunitinib) where opposing mechanisms could produce unpredictable tissue effects [10].

MK-677 is metabolized by CYP3A4. Strong CYP3A4 inhibitors such as ketoconazole or clarithromycin could raise plasma MK-677 concentrations; strong inducers such as rifampin could reduce them. This interaction has not been studied formally but follows standard pharmacokinetic prediction [11].

Who Should Not Use This Stack

The population most at risk from this combination includes individuals with insulin resistance, pre-diabetes, personal or family history of hormone-sensitive malignancies, active inflammatory conditions (where TB-500's angiogenic properties could worsen pathological neovascularization), and anyone taking immunosuppressants or anti-angiogenic medications.

The FDA's broader position on unapproved peptide compounds for human use was summarized in its 2023 guidance clarifying that many peptides, including thymosin beta-4 analogues, are not eligible for compounding under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act because they have been withdrawn from, or never been approved for, human use [5].

Clinicians at HealthRX follow this regulatory framework. When patients inquire about this stack, the default position is to review their complete medical history and lab results before any protocol is considered, with explicit informed consent documentation that covers the research-only status of both compounds.